NeoImmuneTech
Daniel Rho, MS PMP, is a seasoned professional currently serving as Director at NeoImmuneTech, Inc. since August 2022. Previously, Daniel held roles including Senior Manager of Project Management at PTC Therapeutics, Inc. and Senior Project Manager in Strategic Planning at Kolon TissueGene, Inc. Daniel's career began as a Project Manager at JK BioPharma Solutions and also included a position as Marketing Manager at JKosmmune. Earlier experiences involved project coordination and lab technician work at Luminescent MD, LLC, where proprietary biosensors were developed and patented, as well as internships at Brown University and the Harvard-MIT Division of Health Sciences and Technology focusing on protein crystallography and tissue engineering, respectively. Daniel earned a Bachelor of Science in Biochemistry from Brown University and a Master of Science in Physiology from Georgetown University.
This person is not in any teams
NeoImmuneTech
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech